帕博利珠单抗治疗女性下生殖道复发性小细胞神经内分泌癌的疗效与安全性II期研究
这项开放标签、研究者发起的II期篮式试验纳入7例下生殖道复发性小细胞神经内分泌癌女性患者,每3周静脉给予帕博利珠单抗200 mg。主要终点27周无进展生存比例为0,中位无进展间期2.1个月(范围0.8-3.3个月),2/7例(29%)出现≥3级治疗相关不良事件。结论为帕博利珠单抗单药活性极小,多数患者耐受良好。
要点
- 7例患者中无人在27周时无进展,中位无进展间期2.1个月。
- 首次影像评估时1例疾病稳定、6例进展,稳定者14周时进展。
- 2/7例(29%)出现≥3级治疗相关不良事件,均为无症状转氨酶升高。
核心结论
- 帕博利珠单抗单药在女性下生殖道复发性小细胞神经内分泌肿瘤中活性极小。
- 多数研究参与者对治疗耐受良好,严重不良事件发生率低。
研究设计与样本
- 开放标签、研究者发起的II期篮式试验(ClinicalTrials.gov: NCT02721732),预设队列包括肺外来源小细胞恶性肿瘤。
- 入组标准包括研究入组前6个月内标准治疗期间疾病进展。
- 患者于2017年2月至2019年2月入组,每3周静脉给予帕博利珠单抗200 mg。
- 主要终点为27周时无进展生存的患者比例,每9周(3周期)以影像学评估缓解。
- 共纳入7例妇科肺外小细胞癌女性,6例宫颈癌、1例外阴癌。
主要发现
- 无患者在27周时无进展。
- 首次影像学评估时1例疾病稳定、6例疾病进展。
- 6周时疾病稳定的1例患者在14周时疾病进展。
- 中位无进展间期为2.1个月(范围0.8-3.3个月)。
- 7例中2例(29%)出现≥3级治疗相关不良事件:1例为3级无症状血清碱性磷酸酶升高,1例为3级无症状血清丙氨酸氨基转移酶升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of pembrolizumab in women with recurrent small cell neuroendocrine tumors of the lower genital tract. METHODS: We conducted an open-label, investigator-initiated phase II basket trial of pembrolizumab 200 mg intravenously every 3 weeks in patients with rare tumors (ClinicalTrials.gov: NCT02721732). The trial had prespecified cohorts, including small cell malignancies of extrapulmonary origin. Eligibility criteria included disease progression during standard treatment in the 6 months before study enrollment. Patients were enrolled from February 2017 to February 2019. The primary endpoint was the proportion of patients alive without progression at 27 weeks. Response to pembrolizumab was evaluated every 9 weeks (3 cycles) with radiographic imaging. RESULTS: Seven women with gynecologic extrapulmonary small cell carcinoma were enrolled, 6 with cervical and 1 with vulvar carcinoma. No patient was progression free at 27 weeks. At first radiologic assessment, 1 patient had stable disease, while 6 had progression. The single patient with stable disease at 6 weeks had disease progression at 14 weeks. The median progression-free interval was 2.1 months (range 0.8-3.3 months). Severe treatment-related adverse events (≥grade 3) were seen in 2 of 7 patients (29%); 1 patient had grade 3 asymptomatic elevation of serum alkaline phosphatase, and 1 had grade 3 asymptomatic elevation of serum alanine aminotransferase. CONCLUSIONS: Pembrolizumab alone showed minimal activity in women with recurrent small cell neuroendocrine tumors of the lower genital tract. Treatment was well tolerated in the majority of study participants, and the rate of severe adverse events was low.
引用
- Frumovitz M, Westin SN, Salvo G, et al. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020. PMID: 32534809. doi:10.1016/j.ygyno.2020.05.682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。